Thursday's Health Winners & Losers

Also on the decline, drug development services company, PharmaNet (PDGI Quote - Cramer on PDGI - Stock Picks), missed Wall Street's first-quarter views on loss of contract revenue. The company reported a loss of $10.1 million, or 53 cents a share, vs. a profit of $6.6 million, or 35 cents a share, a year prior. Revenue was $107.4 million, actually beating its part of the Thomson Financial consensus target of profit of 30 cents a share on $94.6 million.

The company lowered its full-year guidance to revenue between $390 million and $399 million from previous guidance of $401 million to $409 million.

Jeffries and Co. downgraded the stock to hold from buy and chopped its price target to $15 from $32. Robert Baird also downgraded it, to neutral from outperform, and lowered its price target to $24 from $33.

PharmaNet shares shed $6.70, or 28%, to $17.16 on Thursday.

Another analyst action, JMP Securities upped its price target for Sangamo BioSciences (SGMO Quote - Cramer on SGMO - Stock Picks) -- a day after its earnings -- to $24 from $18. After opening 6 cents lower than the previous close, the company added 4.7%, to $13.35 in recent regular trading.

« Previous Page

1 2 3

Next Page »